Based on this YouTube video's total view count of 52.2K views and industry-standard rates, the estimated total earning is $37 - $104 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Corona remedies IPO review | Corona IPO latest GMP | Wakefit IPO GMP | Nephrocare IPO GMP with 52,214 views, 1,429 likes, and 262 comments. Experience the impact of this video content that has captured audience attention.

Register and be a part of our community https://superprofile.bio/vp/685f9401c345fa001398eb8d Welcome back to the channel! In this video, we bring you a complete breakdown of the Corona Remedies IPO, one of the most talked-about pharma IPOs of 2025. If you are planning to invest for listing gains, long-term compounding, or simply want to understand the fundamentals of this upcoming issue, this detailed description covers everything — updated GMP, correct IPO dates, price band, lot size, and more. 🏥 About Corona Remedies Ltd. Corona Remedies Ltd. is a fast-growing, innovation-focused pharmaceutical company with a strong presence in the chronic and acute therapy markets. The company offers formulations across cardiology, gastroenterology, diabetology, dermatology, gynaecology, respiratory care, pain management, and nutraceuticals. Corona’s growth has been driven by its doctor-prescription-backed brand portfolio, expanding field force, and strengthening domestic presence. The company operates in a highly competitive but fast-expanding Indian pharma market with a clear focus on branded generics — a segment known for superior margins and consistent demand. 📅 Corona Remedies IPO Details (Correct & Updated) ✔ IPO Type: Book Built Issue ✔ Issue Size: ₹655.37 crore (100% Offer for Sale) No fresh issue — all proceeds go to selling shareholders. ✔ Price Band: ₹1,008 – ₹1,062 per share ✔ Lot Size: 14 shares ✔ Minimum Investment (Retail): Approx. ₹14,868 ✔ Listing: NSE & BSE 🗓️ Important IPO Dates IPO Opens: 8 December 2025 IPO Closes: 10 December 2025 Allotment Date: 11 December 2025 Refunds Initiated: 12 December 2025 Shares Credited to Demat: 12 December 2025 Listing Date: 15 December 2025 These are the updated and current dates for the public issue. 📈 Corona Remedies IPO GMP (Latest Market Trend) The Grey Market Premium (GMP) for Corona Remedies has been showing strong positive sentiment as the subscription window approaches. GMP indicates potential listing expectations, but it is not a guarantee, and investors should use it only as a supplementary indicator along with demand, fundamentals, and valuation. 📊 Financial & Business Strengths Corona Remedies displays several strengths that make it attractive to both retail and institutional investors: 🔹 Consistent Financial Growth Steady growth in revenue and profitability backed by branded generics. 🔹 Strong Portfolio in Chronic Therapy Chronic segment contributes significantly to stable cash flows and margins. 🔹 Large Field Force & Distribution Network A robust presence across India through medical representatives and distributors. 🔹 High-Margin Branded Formulations Focus on domestic branded formulations helps maintain pricing power. 🔹 Growing Product Pipeline Introduction of new therapies and expansion into high-demand segments. ⚠️ Risks to Consider Before Applying While the company shows strong fundamentals, there are some risks: ❗ 100% OFS Issue No fresh capital is being raised — all proceeds go to promoters/selling shareholders. ❗ Competitive Pharma Market The Indian pharma sector is crowded, especially in generics. ❗ Regulatory Environment Price caps and changing drug regulations could impact profitability. ❗ Working Capital Heavy Pharma operations require high working capital cycles and credit to distributors. 🧐 Should You Apply? – Expert View by Vibhor Varshney Corona Remedies stands out as a stable, brand-driven pharma company with solid presence in chronic therapies, good financial visibility, and strong demand indicators. The valuation, GMP trend, and brand strength suggest that this IPO may offer: ✔ Potential listing gains ✔ Solid visibility for long-term investors looking for defensive sectors ✔ Moderate risk profile due to strong domestic positioning However, investors should also consider that the issue is entirely OFS, and long-term prospects depend on execution, margin sustainability, and continued demand from chronic therapy markets. 🤝 Stay Connected If you like such in-depth IPO breakdowns, make sure to Like, Share, and Subscribe so you never miss upcoming IPO reviews, GMP updates, and stock market insights. #CoronaRemediesIPO #CoronaRemedies #CoronaIPO #CoronaIPOGMP #CoronaRemediesReview #CoronaRemediesAnalysis #CoronaIPO2025 #IPOReview #IPOGMP #LatestGMP #VibhorVarshney #ShareMarketIndia #StockMarketIndia #IPO2025 #UpcomingIPOs #PharmaIPO #PharmaStocks #LongTermInvesting #ListingGains #PrimaryMarket #EquityMarket #InvestingForBeginners #StockAnalysis #BusinessReview #FinancialAnalysis #NSE #BSE #MarketUpdates #FinanceYouTube #WealthCreation #InvestmentGuide #IndiaMarkets

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.